JPH1135456A - 光活性化ヒペリシンおよびその使用 - Google Patents
光活性化ヒペリシンおよびその使用Info
- Publication number
- JPH1135456A JPH1135456A JP9290518A JP29051897A JPH1135456A JP H1135456 A JPH1135456 A JP H1135456A JP 9290518 A JP9290518 A JP 9290518A JP 29051897 A JP29051897 A JP 29051897A JP H1135456 A JPH1135456 A JP H1135456A
- Authority
- JP
- Japan
- Prior art keywords
- hypericin
- tissue
- mammal
- derivative
- photoactivating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical class C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 title claims abstract 37
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 claims abstract description 189
- 229940005608 hypericin Drugs 0.000 claims abstract description 175
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 claims abstract description 175
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 156
- 238000000034 method Methods 0.000 claims abstract description 90
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 71
- 241000124008 Mammalia Species 0.000 claims abstract description 68
- 201000010099 disease Diseases 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 230000035755 proliferation Effects 0.000 claims abstract description 31
- YLILOANQCQKPOD-UHFFFAOYSA-N protohypericin Chemical compound C12=C(O)C=C(O)C(C(C3=C(O)C=C(C=C33)C)=O)=C2C3=C2C3=C1C(O)=CC(O)=C3C(=O)C1=C(O)C=C(C)C=C12 YLILOANQCQKPOD-UHFFFAOYSA-N 0.000 claims abstract description 30
- YXBUQQDFTYOHQI-UHFFFAOYSA-N Pseudohypericin Chemical compound OC1=CC(O)=C2C(=O)C3=C(O)C=C(C)C4=C3C3=C2C1=C(C(O)=CC(O)=C1C2=O)C1=C3C1=C2C(O)=CC(CO)=C14 YXBUQQDFTYOHQI-UHFFFAOYSA-N 0.000 claims abstract description 28
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 22
- 238000009825 accumulation Methods 0.000 claims abstract description 21
- 230000001678 irradiating effect Effects 0.000 claims abstract description 19
- 210000001519 tissue Anatomy 0.000 claims description 99
- 210000004027 cell Anatomy 0.000 claims description 79
- 230000006907 apoptotic process Effects 0.000 claims description 44
- 210000004369 blood Anatomy 0.000 claims description 30
- 239000008280 blood Substances 0.000 claims description 30
- 230000002186 photoactivation Effects 0.000 claims description 20
- 230000012010 growth Effects 0.000 claims description 19
- 208000032839 leukemia Diseases 0.000 claims description 16
- 230000001185 psoriatic effect Effects 0.000 claims description 16
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 15
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 15
- 201000005962 mycosis fungoides Diseases 0.000 claims description 15
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 11
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 10
- 210000001185 bone marrow Anatomy 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 206010029098 Neoplasm skin Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 5
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 208000024908 graft versus host disease Diseases 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 238000005286 illumination Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 206010014950 Eosinophilia Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 201000006747 infectious mononucleosis Diseases 0.000 claims description 3
- 208000008585 mastocytosis Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 238000006243 chemical reaction Methods 0.000 abstract description 11
- 206010042496 Sunburn Diseases 0.000 abstract description 3
- 230000002411 adverse Effects 0.000 abstract 1
- YDOIFHVUBCIUHF-UHFFFAOYSA-N 9,11,13,16,18,20-hexahydroxy-5,24-dimethyloctacyclo[13.11.1.12,10.03,8.04,25.019,27.021,26.014,28]octacosa-1(26),2,4(25),5,8,10,12,14(28),15(27),16,18,20,23-tridecaene-7,22-dione Chemical compound OC1=CC(O)=C2C(O)=C3C(=O)C=C(C)C4=C5C(C)=CC(=O)C6=C(O)C7=C(O)C=C(O)C8=C7C(=C56)C(=C34)C2=C18 YDOIFHVUBCIUHF-UHFFFAOYSA-N 0.000 description 263
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 47
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 44
- 229960004469 methoxsalen Drugs 0.000 description 44
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 44
- 230000003211 malignant effect Effects 0.000 description 37
- 210000003491 skin Anatomy 0.000 description 31
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 22
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 21
- 210000004698 lymphocyte Anatomy 0.000 description 20
- 230000035508 accumulation Effects 0.000 description 19
- 230000002159 abnormal effect Effects 0.000 description 16
- 230000004663 cell proliferation Effects 0.000 description 13
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 230000001613 neoplastic effect Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 8
- 239000003504 photosensitizing agent Substances 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 235000019445 benzyl alcohol Nutrition 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N furocoumarin Natural products C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000032820 leukocyte apoptotic process Effects 0.000 description 5
- 239000003226 mitogen Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 4
- 238000012288 TUNEL assay Methods 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000006882 induction of apoptosis Effects 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 238000002428 photodynamic therapy Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000005670 electromagnetic radiation Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000006311 Pyoderma Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000005735 apoptotic response Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 2
- 230000004987 nonapoptotic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- -1 psoralen compound Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- 241000223782 Ciliophora Species 0.000 description 1
- 241001465977 Coccoidea Species 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical group O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000248457 Stentor coeruleus Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000034446 negative regulation of leukocyte proliferation Effects 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/887546 | 1997-07-03 | ||
| US08/887,546 US6001882A (en) | 1997-07-03 | 1997-07-03 | Photoactivated hypericin and the use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH1135456A true JPH1135456A (ja) | 1999-02-09 |
| JPH1135456A5 JPH1135456A5 (enExample) | 2005-06-23 |
Family
ID=25391387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9290518A Pending JPH1135456A (ja) | 1997-07-03 | 1997-10-08 | 光活性化ヒペリシンおよびその使用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US6001882A (enExample) |
| JP (1) | JPH1135456A (enExample) |
| CA (1) | CA2217551C (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399298B1 (en) * | 1998-06-30 | 2002-06-04 | Sloan-Kettering Institute For Cancer Research | Ku70—related methods |
| US6524330B1 (en) | 2000-10-27 | 2003-02-25 | Bahram Khoobehi | Method of ocular treatment |
| US6561808B2 (en) * | 2001-09-27 | 2003-05-13 | Ceramoptec Industries, Inc. | Method and tools for oral hygiene |
| US20040038373A1 (en) * | 2001-12-07 | 2004-02-26 | Platz Matthew S. | Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
| US7235392B2 (en) * | 2001-12-07 | 2007-06-26 | The Ohio State University Research Foundation | Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
| US20040259053A1 (en) * | 2003-06-18 | 2004-12-23 | Bekov George I. | Method and apparatus for laser-assisted dental scaling |
| WO2009066294A1 (en) * | 2007-11-20 | 2009-05-28 | Hy Biopharma Inc. | Device and method for photodynamic therapy |
| US8715920B2 (en) | 2010-07-27 | 2014-05-06 | Biovec Transfusion, Llc | Composition for preserving platelets during photosensitization |
| US8629302B2 (en) | 2009-09-15 | 2014-01-14 | Alfonso J. Tobia | Methods for preparing hypericin |
| EP2932973B1 (en) | 2010-05-04 | 2020-04-01 | Soligenix, Inc. | Formulations for use in the treatment of skin conditions |
| IL310029A (en) * | 2021-07-08 | 2024-03-01 | Soligenix Inc | Dermatological preparations and methods for treating CUTANEOUS T-CELL LYMPHOMA |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898891A (en) * | 1987-08-07 | 1990-02-06 | Yeda Research And Development Company Ltd. | Antiviral compositions |
| IL92315A (en) * | 1989-11-15 | 1996-12-05 | Yeda Res & Dev | Preparation of Hypericin from Amodin Enron |
| US5514714A (en) * | 1990-08-23 | 1996-05-07 | New York University | Methods and polycyclic aromatic compound containing compositions for treating T-cell-mediated diseases |
| US5316768A (en) * | 1990-12-28 | 1994-05-31 | Murdock International Corporation | Pharmaceutical compositions having antiviral activity against human cytomegalovirus |
| AU3474593A (en) * | 1992-01-16 | 1993-08-03 | New York University | Hypericin treatment of vaccine agents for improved immunogenicity |
-
1997
- 1997-07-03 US US08/887,546 patent/US6001882A/en not_active Expired - Lifetime
- 1997-10-07 CA CA002217551A patent/CA2217551C/en not_active Expired - Fee Related
- 1997-10-08 JP JP9290518A patent/JPH1135456A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2217551A1 (en) | 1999-01-03 |
| CA2217551C (en) | 2008-08-12 |
| US6001882A (en) | 1999-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baker et al. | Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment | |
| Godar | UVA1 radiation triggers two different final apoptotic pathways | |
| Gluckman et al. | Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation | |
| Treves et al. | Brief communication: immunotherapy of lethal metastases by lymphocytes sensitized against tumor cells in vitro | |
| JPH1135456A (ja) | 光活性化ヒペリシンおよびその使用 | |
| Waldmann et al. | Influence of the major histocompatibility complex on lymphocyte interactions in antibody formation | |
| JPH08501278A (ja) | 血液中の選択的な細胞不活性化 | |
| Ulirich | Photoinactivation of T-cell function with psoralen and UVA radiation suppresses the induction of experimental murine graft-versus-host disease across major histocompatibility barriers | |
| Karu et al. | Changes in oxidative metabolism of murine spleen following laser and superluminous diode (660–950 nm) irradiation: effects of cellular composition and radiation parameters | |
| Vecchi et al. | Phototherapy for neonatal jaundice: clinical equivalence of fluorescent green and “special” blue lamps | |
| CZ2001316A3 (cs) | Způsob přípravy allogenní buněčné populace, populace T-buněk a její pouľití pro potlačení vzniku reakce ątěpu proti hostiteli | |
| Karasek | Melatonin in humans-where we are 40 years after its discovery | |
| McGrath Jr | Ultraviolet A1 (340–400 nm) irradiation and systemic lupus erythematosus | |
| US6653337B2 (en) | Therapy of auto-immune disease by a photochemotherapeutical method | |
| Polla et al. | Enhancement of the elicitation phase of the murine contact hypersensitivity response by prior exposure to local ultraviolet radiation | |
| Liu et al. | Melatonin: a potential therapeutic approach for the management of primary Sjögren’s syndrome | |
| US20050238623A1 (en) | Method for treating mammals with modified mammalian blood | |
| Minehan et al. | The interaction of etoposide with radiation: variation in cytotoxicity with the sequence of treatment | |
| CA2217902A1 (en) | Use of gammahydroxybutyrric acid for the treatment of demential syndromes | |
| US7045124B1 (en) | Pre-conditioning against cell death | |
| FR2639830A1 (fr) | Composition antivirale et ses applications | |
| US6733748B2 (en) | Chronic lymphocytic leukemia treatment | |
| Emerit et al. | Superoxide generation by clastogenic factors | |
| Rosenblum et al. | Improved treatment of a brain-tumor model: Part 1: Advantages of single-over multiple-dose BCNU schedules | |
| MXPA01007111A (es) | Pre-acondicionamiento contra muerte celular. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041008 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041008 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080313 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080624 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080924 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080929 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090407 |